Strasbourg

• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neopla … Recruiting
  2024-514341-10-00 1 2025-05-27 Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractor
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• MODULO Recruiting
  2024-515793-27-01 5 2025-04-30 HIV
• Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub … Recruiting
  2024-510893-25-00 5 2025-04-29 Brain metastases of cancer > brain radionecrosis
• ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2024-512043-22-00 4 2025-04-11 Metastatic prostate cancer
• Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting
  2024-512729-10-00 4 2025-03-27 Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting
  2023-505291-30-01 4 2025-03-06 Triple Negative Breast Cancer with residual disease after neoadjuvant
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-509787-15-00 5 2025-02-17 Patients with localised prostate cancer and high-risk features of rela
• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib … Recruiting
  2023-505330-95-01 4 2025-01-30 Blood cancer
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting
  2023-506350-21-00 4 2025-01-06 Localized, resected, FIGO stage I (2018 classification), uterine leiom
• A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting
  2024-516109-21-00 5 2024-12-09 Polycythaemia Vera (PV)
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• Antiplatelet therapy after successful percutaneous coronary intervention for chronically occluded coronary artery: A prospective, multicentr … Recruiting
  2023-508148-23-01 5 2024-12-02 chronically occluded coronary artery
• Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical tr … Recruiting
  2023-508400-38-00 4 2024-11-29 meningioma
• Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation … Recruiting
  2024-517408-12-00 5 2024-11-28 Patient in end-stage renal disease candidate for a kidney transplant
• Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent … Recruiting
  2024-512297-96-01 4 2024-11-26 Head and neck squamous cell carcinoma
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Pati … Recruiting
  2024-511313-38-00 4 2024-11-17 Soft Tissue Sarcoma
• Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting
  2024-516242-19-00 5 2024-11-05 lupus nephritis

Showing 97–120 of 372 trials